Stay updated on Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial
Sign up to get notified when there's something new on the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page.

Latest updates to the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check59 days agoChange DetectedThe page has been updated to reflect a new version of the trial documentation (v2.15.0) and includes the name of the principal investigator, Melissa Accordino, MD, from Columbia University, as well as the addition of the term 'Metastatic Breast Cancer' and the trial identifier 'AAAP9506'.SummaryDifference52%
- Check66 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check74 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
Stay in the know with updates to Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ribociclib Efficacy After CDK4/6 Inhibit Progression Clinical Trial page.